Tortugas Neuroscience, a newly launched biotech startup, is expanding the horizons of the Chinese biotech industry beyond obesity and cancer treatments. The company debuted on Tuesday with a mission to develop and commercialize four innovative drugs targeting severe neurological and psychiatric conditions.
The startup has secured $106 million in funding from Cure Ventures, The Column Group, and AN Ventures to advance its pipeline in the United States.
Licensed Drugs and Development Pipeline
Tortugas Neuroscience has licensed two drugs from Jiangsu Hansoh Pharmaceutical Group to address:
- Schizophrenia
- Tinnitus
Additionally, the company will evaluate two other medicines originally developed by Eisai Co. Ltd. for:
- Focal epilepsy
- Encephalopathies
Clinical Trials and Next Steps
The company plans to initiate mid-stage clinical trials in the U.S. to assess the safety and efficacy of these four drugs. The funding will support these trials as Tortugas Neuroscience aims to bring new therapeutic options to patients with limited treatment choices.
For further details, continue to STAT+.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Who Will Lead the FDA Next? The Search for a New Commissioner Heats Up
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to...